1. Home
  2. HOPE vs ANIP Comparison

HOPE vs ANIP Comparison

Compare HOPE & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hope Bancorp Inc.

HOPE

Hope Bancorp Inc.

N/A

Current Price

$13.43

Market Cap

1.7B

Sector

Finance

ML Signal

N/A

Logo ANI Pharmaceuticals Inc.

ANIP

ANI Pharmaceuticals Inc.

N/A

Current Price

$73.23

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HOPE
ANIP
Founded
1986
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2000
1999

Fundamental Metrics

Financial Performance
Metric
HOPE
ANIP
Price
$13.43
$73.23
Analyst Decision
Buy
Buy
Analyst Count
5
9
Target Price
$15.50
★ $105.78
AVG Volume (30 Days)
★ 666.2K
308.3K
Earning Date
10-27-2026
11-06-2026
Dividend Yield
★ 4.21%
N/A
EPS Growth
N/A
★ 419.23
EPS
0.49
★ 2.32
Revenue
N/A
★ $206,547,000.00
Revenue This Year
$24.46
$25.00
Revenue Next Year
$22.15
$11.39
P/E Ratio
★ $27.39
$31.23
Revenue Growth
N/A
★ 2.47
52 Week Low
$9.80
$69.58
52 Week High
$14.59
$96.99

Technical Indicators

Market Signals
Indicator
HOPE
ANIP
Relative Strength Index (RSI) 29.17 46.02
Support Level $13.09 $69.87
Resistance Level $13.29 $83.03
Average True Range (ATR) 0.26 2.38
MACD -0.08 0.01
Stochastic Oscillator 2.70 32.59

Price Performance

Historical Comparison
HOPE
ANIP

About HOPE Hope Bancorp Inc.

Hope Bancorp Inc is a bank holding company engaged in providing financial services. It offers core business banking products for small and medium-sized businesses and individuals. Services offered by the bank include online banking, mobile banking, mortgage loans, credit cards, investment and wealth management services, and other banking services.

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.

Share on Social Networks: